Details of the Drug Combination

General Information of Drug Combination (ID: DC7YHXU)

Drug Combination Name
Beclomethasone dipropionate Budesonide
Indication
Disease Entry Status REF
Chronic Obstructive Pulmonary Disease Phase 3 [1]
Component Drugs Beclomethasone dipropionate   DM5NW1E Budesonide   DMJIBAW
N.A. Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Beclomethasone dipropionate
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [2]
Nasal polyp CA0J Approved [2]
Rhinitis FA20 Approved [2]
Vasomotor/allergic rhinitis CA08 Approved [2]
Asthma CA23 Investigative [2]
Beclomethasone dipropionate Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Beclomethasone dipropionate Interacts with 42 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [6]
Tartrate-resistant acid phosphatase type 5 (ACP5) OTBV4498 PPA5_HUMAN Decreases Activity [9]
Catalase (CAT) OTHEBX9R CATA_HUMAN Increases Expression [10]
Glutathione hydrolase 5 proenzyme (GGT5) OTDJYEO7 GGT5_HUMAN Increases Expression [11]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases Expression [12]
Nitric oxide synthase, inducible (NOS2) OTKKIOJ1 NOS2_HUMAN Decreases Expression [13]
Cytosolic phospholipase A2 (PLA2G4A) OTE70SOT PA24A_HUMAN Decreases Activity [14]
Phosphatidylcholine translocator ABCB4 (ABCB4) OTE6PY83 MDR3_HUMAN Increases Expression [6]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Increases Expression [6]
Cytochrome P450 2S1 (CYP2S1) OTKHX4RF CP2S1_HUMAN Decreases Expression [15]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Increases Expression [16]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [17]
Metalloproteinase inhibitor 1 (TIMP1) OTOXC51H TIMP1_HUMAN Increases Expression [18]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Decreases Expression [19]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Secretion [20]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Expression [21]
Interleukin-2 receptor subunit alpha (IL2RA) OT0MWCHG IL2RA_HUMAN Decreases Expression [22]
C-X-C motif chemokine 10 (CXCL10) OTTLQ6S0 CXL10_HUMAN Decreases Secretion [23]
Lactotransferrin (LTF) OT8JWCZ0 TRFL_HUMAN Decreases Secretion [24]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [25]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Secretion [26]
Interleukin-5 (IL5) OTAFPSCO IL5_HUMAN Decreases Expression [27]
Prostate-specific antigen (KLK3) OTFGSBFJ KLK3_HUMAN Increases Expression [28]
Beta-2 adrenergic receptor (ADRB2) OTSDOX4Q ADRB2_HUMAN Increases Expression [29]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [30]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Decreases Activity [31]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Decreases Expression [32]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [7]
Non-secretory ribonuclease (RNASE2) OT8Z4FNE RNAS2_HUMAN Decreases Expression [33]
Eosinophil cationic protein (RNASE3) OTVE2XD1 ECP_HUMAN Decreases Expression [34]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [7]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [7]
C-C motif chemokine 5 (CCL5) OTSCA5CK CCL5_HUMAN Decreases Expression [35]
Matrix metalloproteinase-9 (MMP9) OTB2QDAV MMP9_HUMAN Decreases Expression [18]
Interleukin-1 receptor antagonist protein (IL1RN) OT308CBE IL1RA_HUMAN Decreases Expression [32]
Interleukin-10 (IL10) OTIRFRXC IL10_HUMAN Decreases Secretion [20]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Activity [36]
B1 bradykinin receptor (BDKRB1) OT1DHSVQ BKRB1_HUMAN Decreases Expression [37]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [38]
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Activity [39]
11-beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) OTHF4H9U DHI2_HUMAN Increases Metabolism [40]
Pyrin (MEFV) OTRJ6S6K MEFV_HUMAN Increases Response To Substance [41]
------------------------------------------------------------------------------------
⏷ Show the Full List of 42 DOT(s)
Indication(s) of Budesonide
Disease Entry ICD 11 Status REF
Allergic rhinitis CA08.0 Approved [3]
Asthma CA23 Approved [4]
Crohn disease DD70 Approved [3]
Inflammatory bowel disease DD72 Approved [3]
Radiation proctitis N.A. Approved [3]
Ulcerative colitis DD71 Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 3 [5]
Budesonide Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Glucocorticoid receptor (NR3C1) TTYRL6O GCR_HUMAN Antagonist [42]
------------------------------------------------------------------------------------
Budesonide Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [43]
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [44]
------------------------------------------------------------------------------------
Budesonide Interacts with 28 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Increases Expression [45]
Metallothionein-2 (MT2A) OTHOACHD MT2_HUMAN Increases Expression [46]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Expression [46]
Cytochrome P450 3A5 (CYP3A5) OTSXFBXB CP3A5_HUMAN Increases Expression [12]
Cytosolic phospholipase A2 (PLA2G4A) OTE70SOT PA24A_HUMAN Decreases Activity [14]
Organic solute transporter subunit alpha (SLC51A) OTDJRZ0P OSTA_HUMAN Increases Expression [45]
Organic solute transporter subunit beta (SLC51B) OT4WYPSR OSTB_HUMAN Increases Expression [45]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [47]
Nuclear receptor subfamily 1 group I member 2 (NR1I2) OTC5U0N5 NR1I2_HUMAN Increases Activity [48]
Tumor necrosis factor (TNF) OT4IE164 TNFA_HUMAN Decreases Expression [49]
Interferon gamma (IFNG) OTXG9JM7 IFNG_HUMAN Decreases Secretion [50]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Decreases Secretion [50]
Lactotransferrin (LTF) OT8JWCZ0 TRFL_HUMAN Decreases Secretion [24]
Osteocalcin (BGLAP) OTK1YLWQ OSTCN_HUMAN Decreases Expression [51]
Granulocyte-macrophage colony-stimulating factor (CSF2) OT1M7D28 CSF2_HUMAN Decreases Secretion [26]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Expression [52]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [53]
Mineralocorticoid receptor (NR3C2) OT0F2V2Z MCR_HUMAN Increases Activity [30]
C-C motif chemokine 3 (CCL3) OTW2H3ND CCL3_HUMAN Increases Expression [7]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [52]
Eosinophil cationic protein (RNASE3) OTVE2XD1 ECP_HUMAN Decreases Expression [54]
C-C motif chemokine 4 (CCL4) OT6B8P25 CCL4_HUMAN Increases Expression [7]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Decreases Expression [7]
Interleukin-4 receptor subunit alpha (IL4R) OTTXOTCW IL4RA_HUMAN Decreases Expression [55]
Interleukin-13 (IL13) OTI4YS3Y IL13_HUMAN Increases Activity [36]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [38]
C-C motif chemokine 17 (CCL17) OTIKW21L CCL17_HUMAN Decreases Expression [55]
T-box transcription factor TBX21 (TBX21) OT3UK5KE TBX21_HUMAN Increases Response [56]
------------------------------------------------------------------------------------
⏷ Show the Full List of 28 DOT(s)

References

1 ClinicalTrials.gov (NCT00476099) Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD
2 Beclomethasone dipropionate FDA Label
3 Budesonide FDA Label
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7434).
5 Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia
6 Induction of drug-metabolizing enzymes and transporters in human bronchial epithelial cells by beclomethasone dipropionate. IUBMB Life. 2004 Jun;56(6):355-9.
7 Cell-based and cytokine-directed chemical screen to identify potential anti-multiple myeloma agents. Leuk Res. 2010 Jul;34(7):917-24. doi: 10.1016/j.leukres.2009.12.002. Epub 2010 Feb 8.
8 Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302.
9 Bone metabolism in children with asthma treated with inhaled beclomethasone dipropionate. J Pediatr. 1993 Feb;122(2):219-26.
10 Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate. Eur Respir J. 1999 Jun;13(6):1260-6.
11 A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism. J Allergy Clin Immunol. 2001 Jul;108(1):122-4.
12 Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. J Pharmacol Exp Ther. 2003 Feb;304(2):745-52.
13 Correlation between change in pulmonary function and suppression of reactive nitrogen species production following steroid treatment in COPD. Thorax. 2003 Apr;58(4):299-305.
14 Comparison of in vitro-activity of commonly used topical glucocorticoids on cytokine- and phospholipase inhibition. Eur J Med Res. 2004 Aug 31;9(8):383-90.
15 CYP2S1 is negatively regulated by corticosteroids in human cell lines. Toxicol Lett. 2012 Feb 25;209(1):30-4.
16 Regulation of CYP3A genes by glucocorticoids in human lung cells. F1000Res. 2013 Aug 13;2:173.
17 Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening. Drug Metab Dispos. 2011 Feb;39(2):337-44. doi: 10.1124/dmd.110.035808. Epub 2010 Nov 10.
18 Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of the balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J Allergy Clin Immunol. 1999 Aug;104(2 Pt 1):356-63. doi: 10.1016/s0091-6749(99)70379-9.
19 Glucocorticoids decrease c-fos expression in human nasal polyps in vivo. Thorax. 1998 Jul;53(7):577-82. doi: 10.1136/thx.53.7.577.
20 Phosphodiesterase type 4 inhibitors, but not glucocorticoids, are more potent in suppression of cytokine secretion by mononuclear cells from atopic than nonatopic donors. J Allergy Clin Immunol. 1998 Nov;102(5):797-804. doi: 10.1016/s0091-6749(98)70020-x.
21 Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium. Thorax. 1997 May;52(5):407-10. doi: 10.1136/thx.52.5.407.
22 Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med. 1994 Jan;149(1):86-90. doi: 10.1164/ajrccm.149.1.8111605.
23 The role of IFN-gamma in regulation of IFN-gamma-inducible protein 10 (IP-10) expression in lung epithelial cell and peripheral blood mononuclear cell co-cultures. Respir Res. 2007 Nov 8;8(1):80. doi: 10.1186/1465-9921-8-80.
24 Effects of topical glucocorticoids on in vitro lactoferrin glandular secretion: comparison between human upper and lower airways. J Allergy Clin Immunol. 2000 Dec;106(6):1053-62. doi: 10.1067/mai.2000.110476.
25 A large volume spacer significantly reduces the effect of inhaled steroids on bone formation. Postgrad Med J. 1995 Mar;71(833):156-9. doi: 10.1136/pgmj.71.833.156.
26 Inhibition of GM-CSF secretion by topical corticosteroids and nedocromil sodium. A comparison study using nasal polyp epithelial cells. Respir Med. 2000 May;94(5):428-31. doi: 10.1053/rmed.1999.0756.
27 Differential potency of beclomethasone esters in-vitro on human T-lymphocyte cytokine production and osteoblast activity. J Pharm Pharmacol. 2000 Apr;52(4):417-23. doi: 10.1211/0022357001774174.
28 Expression of the prostate specific antigen gene by lung tissue. Clin Cancer Res. 1997 Jul;3(7):1201-6.
29 Biochemical interaction between effects of beclomethasone dipropionate and salbutamol or formoterol in sputum cells from mild to moderate asthmatics. Allergy. 2005 Mar;60(3):323-9. doi: 10.1111/j.1398-9995.2005.00702.x.
30 Transactivation via the human glucocorticoid and mineralocorticoid receptor by therapeutically used steroids in CV-1 cells: a comparison of their glucocorticoid and mineralocorticoid properties. Eur J Endocrinol. 2004 Sep;151(3):397-406. doi: 10.1530/eje.0.1510397.
31 Anti-proliferative and anti-remodelling effect of beclomethasone dipropionate, formoterol and salbutamol alone or in combination in primary human bronchial fibroblasts. Allergy. 2008 Apr;63(4):432-7. doi: 10.1111/j.1398-9995.2007.01582.x. Epub 2007 Dec 8.
32 Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia. Pediatr Pulmonol. 2000 Oct;30(4):275-81. doi: 10.1002/1099-0496(200010)30:4<275::aid-ppul1>3.0.co;2-g.
33 Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma. Eur Respir J. 2002 Jul;20(1):66-72. doi: 10.1183/09031936.02.00094202.
34 Effect of inhaled beclomethasone dipropionate and budesonide dry powder on pulmonary function and serum eosinophil cationic protein in adult asthmatics. J Investig Allergol Clin Immunol. 1999 Jul-Aug;9(4):241-7.
35 Expression of RANTES by human bronchial epithelial cells in vitro and in vivo and the effect of corticosteroids. Am J Respir Cell Mol Biol. 1996 Jan;14(1):27-35. doi: 10.1165/ajrcmb.14.1.8534483.
36 [Effects of beclomethasone dipropionate and budesonide on interleukin-13 induced cytokine release, proliferation and differentiation of the human lung fibroblasts]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Aug;30(8):599-604.
37 Comparison of kinin B(1) and B(2) receptor expression in neutrophils of asthmatic and non-asthmatic subjects. Int Immunopharmacol. 2007 Dec 20;7(14):1862-8. doi: 10.1016/j.intimp.2007.07.012. Epub 2007 Aug 6.
38 Apoptosis of airway epithelial cells induced by corticosteroids. Am J Respir Crit Care Med. 2001 Nov 15;164(10 Pt 1):1939-47. doi: 10.1164/ajrccm.164.10.2103013.
39 Modulation of p-glycoprotein and breast cancer resistance protein by some prescribed corticosteroids. Eur J Pharmacol. 2006 Feb 15;531(1-3):25-33. doi: 10.1016/j.ejphar.2005.12.010. Epub 2006 Jan 25.
40 Metabolism of synthetic steroids by the human placenta. Placenta. 2007 Jan;28(1):39-46.
41 The familial Mediterranean fever gene as a modifier of periodic fever, aphthous stomatitis, pharyngitis, and adenopathy syndrome. Semin Arthritis Rheum. 2011 Apr;40(5):467-72. doi: 10.1016/j.semarthrit.2010.06.009. Epub 2010 Sep 9.
42 PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
43 No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
44 Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5.
45 Expression and regulation of the bile acid transporter, OSTalpha-OSTbeta in rat and human intestine and liver. Biopharm Drug Dispos. 2009 Jul;30(5):241-58.
46 Interaction between glucocorticoids and beta2-agonists: alpha and beta glucocorticoid-receptor mRNA expression in human bronchial epithelial cells. Biochem Pharmacol. 1998 Dec 15;56(12):1561-9.
47 Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11). Toxicol Sci. 2013 Dec;136(2):328-43.
48 Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. Toxicol Lett. 2015 Jan 5;232(1):193-202. doi: 10.1016/j.toxlet.2014.10.009. Epub 2014 Oct 16.
49 Novel sulfhydryl-reactive compounds orazipone and OR-1958 inhibit cytokine production and histamine release in rat and human mast cells. Int Immunopharmacol. 2005 Jan;5(1):177-84. doi: 10.1016/j.intimp.2004.07.020.
50 Evaluation of the inhibitory effects of budesonide on the mitogen-induced or the allergen-induced activation of blood mononuclear cells isolated from asthmatic patients. Ann Allergy Asthma Immunol. 1995 Jul;75(1):33-40.
51 The effects of inhaled glucocorticoids on bone mass and biochemical markers of bone homeostasis: a 1-year study of beclomethasone versus budesonide. Neth J Med. 1997 Jun;50(6):233-7. doi: 10.1016/s0300-2977(96)00081-2.
52 A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res. 2004 Oct 1;10(19):6502-11. doi: 10.1158/1078-0432.CCR-04-0686.
53 Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol. 2012 May 1;260(3):294-302. doi: 10.1016/j.taap.2012.03.008. Epub 2012 Mar 23.
54 Effects of different anti-asthmatic agents on induced sputum and eosinophil cationic protein in mild asthmatics. Respirology. 2004 Nov;9(4):514-20. doi: 10.1111/j.1440-1843.2004.00631.x.
55 Effect of inhaled corticosteroid on an immunoreactive thymus and activation-regulated chemokine expression in the bronchial biopsies from asthmatics. Allergy. 2005 Mar;60(3):317-22. doi: 10.1111/j.1398-9995.2005.00694.x.
56 TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci U S A. 2004 Dec 28;101(52):18099-104. doi: 10.1073/pnas.0408532102. Epub 2004 Dec 16.